Related Experiment Videos
Pneumococcal vaccine in children and young adults with chronic renal disease
A Fuchshuber1, O Kühnemund, B Keuth
1University Children's Hospital of Cologne, Germany.
Insights
Pneumococcal vaccination in children with chronic kidney disease shows a strong initial immune response that wanes significantly within a year. Monitoring antibody levels post-vaccination is crucial for these immunocompromised patients.
Area of Science:
- Pediatric Nephrology
- Immunology
- Vaccinology
Background:
- Pneumococcal vaccination is recommended for immunocompromised children, including those with chronic renal disease.
- The efficacy of pneumococcal vaccination and revaccination in this population remains debated.
Purpose of the Study:
- To evaluate the immunogenicity and durability of pneumococcal vaccination in children and young adults with chronic renal diseases.
- To assess the response to revaccination in this patient group.
Main Methods:
- Forty patients with various chronic renal diseases received a 23-valent pneumococcal vaccine.
- Antibody titers were measured at baseline, 4 weeks, 6 months, and 12 months post-vaccination.
- Twenty-two patients underwent revaccination after 1 year and were monitored for immune response.
Main Results:
- 83% achieved a sufficient immune response at 4 weeks, decreasing to 48% at 1 year.
- Revaccination elicited a response in 50% of patients, but antibody levels declined rapidly within 6 months.
- The vaccine was well-tolerated with no major side effects.
Conclusions:
- The pneumococcal vaccine is safe and elicits an initial immune response in pediatric patients with chronic renal disease.
- Antibody levels decline significantly within 6 months, necessitating monitoring.
- Further research is needed to determine the optimal revaccination strategy.
Background:
Pneumococcal vaccination has been recommended for immunocompromised children over 2 years including patients with chronic renal disease. However, the effect of vaccination and revaccination is variable and the indication for immunization is a subject of controversy.
Methods:
Forty children and young adults with chronic renal diseases (including the idiopathic nephrotic syndrome, chronic renal failure, patients undergoing dialysis and after transplantation) were vaccinated with a 23-valent pneumococcal vaccine. The efficacy of the vaccine was evaluated by measuring antibody titres before and 4 weeks, 6 months, and 12 months after vaccination. Twenty-two patients were submitted to a revaccination 1 year after the first vaccination.
Results:
A sufficient immune response, defined as an at least fourfold increase of postvaccinal antibody titres and an antibody titre > 200, was observed in 83% of the patients 4 weeks after vaccination, but only in 68% after 6 months, and in 48% after 1 year. Revaccination produced a significant immune response in 11/22 patients (50%) followed by a rapid decline of antibody levels within 6 months. Both vaccinations were well tolerated.
Conclusions:
The currently available vaccine is without major side-effects and effective in producing a significant immune response. Antibody levels should be monitored in vaccinated patients with chronic renal diseases considering the rapid decline as early as 6 months after vaccination. Evaluation of the efficacy of revaccination in these patients requires further investigations.